Skip to content

Released May 9, 2022, after the close

10-Q filed May 9, 2022, 39 days after period end · 0000950170-22-008531

Q1 2022 · 10-Q
Revenue$5.90M−59.8% vs Q1 2021−44.6% vs Q4 2021
Net Income-$39.11MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.84N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$39,132,000N/M
Operating Cash Flow-$35,255,000N/M
Margins · derived
Operating margin-663.6%−533.9 pt vs Q1 2021
Net margin-663.2%−456.1 pt vs Q1 2021

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020Q1 2019
Revenue$5.90M$14.66M$7.15M$8.63M
Net Income-$39.11M-$30.36M-$19.60M-$14.25M
EPS Diluted-$0.84-$0.66-$0.84-$0.62

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR